Roche’s Ionify steroid assays receive CLIA ‘moderate complexity’ designation
Original story from Roche Diagnostics (Basel, Switzerland).
Roche has announced that the U.S. Food and Drug Administration has categorized its Ionify® steroid assays for mass spectrometry as ‘moderate complexity’ under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). This designation marks an important step toward expanding access to advanced diagnostic testing, which has historically been limited to highly specialized laboratories due to complex workflows and the need for expert operators.
The Ionify steroid assays include Estradiol, DHEA, DHEA-S, Progesterone, 17-Hydroxyprogesterone and Androstenedione, which run on Roche’s cobas® i 601 analyzer as part of the cobas mass spec solution. By combining the sensitivity and specificity of mass spectrometry with a standardized, easy-to-use workflow, the cobas mass spec solution streamlines complex testing and helps reduce variability across laboratories.
“This technology fundamentally transforms mass spectrometry, moving it from an intricate specialty process to a seamless engine for routine diagnostics,” commented Brad Moore, President and CEO, Roche Diagnostics North America. “By delivering a broad and expanding mass spectrometry menu with automation and standardization, we are empowering laboratories to operate more efficiently and enabling clinicians to make critical decisions sooner – helping ensure the right treatment reaches the right patient without delay.”
You may also be interested in:
- EasyM® Blood-Based MRD Test for Multiple Myeloma
- Yourgene Health Cystic Fibrosis Base Assay Awarded IVDR Accreditation
- Understanding the FDA’s Final CSA Guidance
The Ionify steroid assays, together with the previously launched Ionify 25-Hydroxy Vitamin D total assay, form the growing US portfolio for the cobas mass spec solution with a CLIA ‘moderate complexity’ designation. This classification significantly broadens accessibility, enabling laboratories to routinely offer clinical mass spectrometry assays without the need for specialized operators. Roche remains committed to expanding this menu and maintains an active pipeline of future clinical mass spectrometry assays currently in development and under regulatory review to further extend system and assay availability.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source.
